Moleculin Biotech Inc. (MBRX)
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
📈 **POSITIVE** • High confidence analysis (83%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (89%) **Content type:** Clinical